Crispr Therapeutics shares tumble after significant earnings miss
LONDON - ImmuPharma PLC (LSE:IMM), a drug discovery and development company, is set to attend the Bio-Europe Spring Conference taking place from March 17 to March 19, 2025, in Milan. The company’s top executives, including CEO Tim McCarthy, COO Dr. Tim Franklin, and Dr. Sebastien Goudreau, CEO of ImmuPharma Biotech, will be present at the event.
The Bio-Europe Spring conference is a significant event for the biopharmaceutical and life sciences industry, expected to draw over 3,700 executives and enable more than 20,000 one-on-one meetings. This gathering serves as a critical platform for networking among biotech companies, pharmaceutical firms, investors, and academic institutions.
Tim McCarthy expressed the company’s intent to build on the positive discussions with global BioPharma companies and to continue pursuing commercial deals for ImmuPharma’s portfolio. This event will also provide an opportunity for ImmuPharma to present recent insights into the mechanism of action (MOA) of its P140 technology platform, following an update announcement issued on March 13, 2025.
The attendance at Bio-Europe Spring is a part of ImmuPharma’s ongoing efforts to engage with potential partners and investors to advance its drug development initiatives. The conference aligns with the company’s strategic goals of expanding its commercial reach and fostering collaborations within the industry.
This news is based on a press release statement from ImmuPharma PLC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.